Preview: Natera's Earnings
Natera's Prospera Heart With DQS Cuts False Positives By Over 37%, Outperforming Dd-cfDNA Percentage Alone, AJT Publication Shows
Natera Reports Outcomes From Study of MRD Test for Soft Tissue and Bone Sarcomas
Craig-Hallum Maintains Natera(NTRA.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Envista Holdings (NVST) and Natera (NTRA)
Natera Announces Results of Signatera Study
Express News | Natera's Signatera Shows 93% Sensitivity In Leiomyosarcoma, Most Common Sarcoma Subtype In Study
Largest Sarcoma Study to Date With CtDNA Analysis Demonstrates Excellent Performance for Signatera
Peering Into Natera's Recent Short Interest
Press Release: Natera to Report Its First Quarter Results on May 8, 2025
Express News | Natera Shares Are Trading Lower. The Company Reported Results From Its DEFINE-HT Clinical Trial
Natera: Results Of DEFINE-HT Clinical Trial Shows Prospera Heart Is Predictive Of Clinical Outcomes And Outperforms Biopsy In Predicting Graft Dysfunction
Natera Announces That Its Ultra-Sensitive Signatera Genome Assay Is Now Broadly Available To Physicians In The United States.
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera Genome MRD Test
Natera To Present Data From 8 Studies at 2025 AACR Annual Meeting
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
Natera (NasdaqGS:NTRA) Climbs 11% in One Week
When Will Natera, Inc. (NASDAQ:NTRA) Turn A Profit?
Natera Is Maintained at Overweight by Barclays
Natera Analyst Ratings